The risk of suffering a serious blood clot following AstraZeneca’s vaccine has doubled in a fortnight, according to the latest figures from the UK’s Medicines Healthcare Regulatory Agency (MHRA). Cases have risen from 79 to 168 since April 8, and deaths from 19 to 32.
The risk of suffering a blood clot has also risen from one in 250,000 to one in 126,600, an increase from four per million to 7.9 per million.
Earlier this month, the Joint Committee on Vaccination and Immunization (JCVI) advised that those under 30 be offered an alternative to AstraZeneca’s vaccine because the risk no longer outweighs the benefits for younger people.
The JCVI will carefully examine the new data to assess whether the risk is still worthwhile for older age groups, now that the risk of getting a blood clot has increased.
The MHRA urged people to seek urgent medical attention if they experience a severe headache starting about four days after vaccination, which does not improve with painkillers and worsens when lying down or bending over.
It also advises seeking help if the headache was accompanied by blurred vision, confusion, slurred speech, weakness, drowsiness or seizures.
The regulatory agency asked people to watch for a rash that looks like a small bruise or bleeding under the skin, shortness of breath, chest pain, swelling in the legs and persistent stomach pain.